Print
Senate File 282 - IntroducedA Bill ForAn Act 1relating to the medical use of cannabidiol including
2the rescheduling of a cannabidiol investigational product
3approved as a prescription drug medication under federal law
4and including effective date provisions.
5BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
1 Section 1. Section 124.201, Code 2017, is amended by adding
2the following new subsection:
3 NEW SUBSECTION. 5. a. If a cannabidiol investigational
4product approved as a prescription drug medication by the
5United States food and drug administration is designated
6as a schedule II controlled substance by the federal drug
7enforcement agency, the board shall, upon notice of the
8designation, similarly designate the prescription drug
9medication as a schedule II controlled substance under this
10chapter. Such designation by the board shall be immediately
11effective upon the date of publication in the federal register
12of the final order designating the prescription drug medication
13as a schedule II controlled substance.
14b. The board shall adopt rules pursuant to chapter 17A to
15administer this subsection. The board may adopt rules on an
16emergency basis as provided in section 17A.4, subsection 3, and
17section 17A.5, subsection 2, to administer this subsection,
18and the rules shall be effective immediately upon filing
19unless a later date is specified in the rules. Any emergency
20rules adopted in accordance with this subsection shall also be
21published as a notice of intended action as provided in section
2217A.4, subsection 1.
23 Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed.
24 Sec. 3. EFFECTIVE DATE. The section of this Act repealing
25section 124D.8, Code 2017, takes effect June 30, 2017.
26EXPLANATION
27The inclusion of this explanation does not constitute agreement with
28the explanation’s substance by the members of the general assembly.
29This bill relates to the medical use of cannabidiol,
30including the rescheduling of a cannabidiol investigational
31product approved as a prescription drug medication under
32federal law.
33The bill provides if a cannabidiol investigational product
34approved as a prescription drug medication by the United States
35food and drug administration is designated as a schedule II
-1-1controlled substance by the federal drug enforcement agency,
2the board of pharmacy shall, upon notice of the designation,
3similarly designate the prescription drug medication as
4a schedule II controlled substance. Such designation by
5the board shall be immediately effective upon the date
6of publication in the federal register of the final order
7designating the prescription drug medication as a schedule II
8controlled substance.
9The bill provides that the board shall adopt rules pursuant
10to Code chapter 17A to administer the bill and may adopt
11emergency rules which shall be effective immediately upon
12filing unless a later date is specified in the rules. Any
13emergency rules adopted shall also be published as a notice of
14intended action as provided in Code section 17A.4, subsection
151.
16The bill strikes the repeal of Code chapter 124D (medical
17cannabidiol Act) before the repeal becomes effective July 1,
182017.
-2-rh/rj
2the rescheduling of a cannabidiol investigational product
3approved as a prescription drug medication under federal law
4and including effective date provisions.
5BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
1 Section 1. Section 124.201, Code 2017, is amended by adding
2the following new subsection:
3 NEW SUBSECTION. 5. a. If a cannabidiol investigational
4product approved as a prescription drug medication by the
5United States food and drug administration is designated
6as a schedule II controlled substance by the federal drug
7enforcement agency, the board shall, upon notice of the
8designation, similarly designate the prescription drug
9medication as a schedule II controlled substance under this
10chapter. Such designation by the board shall be immediately
11effective upon the date of publication in the federal register
12of the final order designating the prescription drug medication
13as a schedule II controlled substance.
14b. The board shall adopt rules pursuant to chapter 17A to
15administer this subsection. The board may adopt rules on an
16emergency basis as provided in section 17A.4, subsection 3, and
17section 17A.5, subsection 2, to administer this subsection,
18and the rules shall be effective immediately upon filing
19unless a later date is specified in the rules. Any emergency
20rules adopted in accordance with this subsection shall also be
21published as a notice of intended action as provided in section
2217A.4, subsection 1.
23 Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed.
24 Sec. 3. EFFECTIVE DATE. The section of this Act repealing
25section 124D.8, Code 2017, takes effect June 30, 2017.
26EXPLANATION
27The inclusion of this explanation does not constitute agreement with
28the explanation’s substance by the members of the general assembly.
29This bill relates to the medical use of cannabidiol,
30including the rescheduling of a cannabidiol investigational
31product approved as a prescription drug medication under
32federal law.
33The bill provides if a cannabidiol investigational product
34approved as a prescription drug medication by the United States
35food and drug administration is designated as a schedule II
-1-1controlled substance by the federal drug enforcement agency,
2the board of pharmacy shall, upon notice of the designation,
3similarly designate the prescription drug medication as
4a schedule II controlled substance. Such designation by
5the board shall be immediately effective upon the date
6of publication in the federal register of the final order
7designating the prescription drug medication as a schedule II
8controlled substance.
9The bill provides that the board shall adopt rules pursuant
10to Code chapter 17A to administer the bill and may adopt
11emergency rules which shall be effective immediately upon
12filing unless a later date is specified in the rules. Any
13emergency rules adopted shall also be published as a notice of
14intended action as provided in Code section 17A.4, subsection
151.
16The bill strikes the repeal of Code chapter 124D (medical
17cannabidiol Act) before the repeal becomes effective July 1,
182017.
-2-rh/rj